Blueprint Medicines Corporation

DB:2L9 Stock Report

Market Cap: €6.8b

Blueprint Medicines Valuation

Is 2L9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2L9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€417.62
Fair Value
74.3% undervalued intrinsic discount
19
Number of Analysts

Below Fair Value: 2L9 (€107.4) is trading below our estimate of fair value (€417.62)

Significantly Below Fair Value: 2L9 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2L9?

Key metric: As 2L9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2L9. This is calculated by dividing 2L9's market cap by their current revenue.
What is 2L9's PS Ratio?
PS Ratio16.3x
SalesUS$434.42m
Market CapUS$7.08b

Price to Sales Ratio vs Peers

How does 2L9's PS Ratio compare to its peers?

The above table shows the PS ratio for 2L9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.9x
BIO3 Biotest
1.6x3.6%€1.4b
FYB Formycon
15.5x24.6%€918.2m
HPHA Heidelberg Pharma
13.5x16.6%€112.8m
2INV 2invest
8.8xn/a€67.8m
2L9 Blueprint Medicines
16.3x23.5%€7.1b

Price-To-Sales vs Peers: 2L9 is expensive based on its Price-To-Sales Ratio (16.3x) compared to the peer average (9.7x).

Price to Sales Ratio vs Industry

How does 2L9's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
2L9 16.3xIndustry Avg. 8.4xNo. of Companies5PS0612182430+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 2L9 is expensive based on its Price-To-Sales Ratio (16.3x) compared to the European Biotechs industry average (8.5x).

Price to Sales Ratio vs Fair Ratio

What is 2L9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2L9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.3x
Fair PS Ratio7.2x

Price-To-Sales vs Fair Ratio: 2L9 is expensive based on its Price-To-Sales Ratio (16.3x) compared to the estimated Fair Price-To-Sales Ratio (7.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2L9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€107.40
€121.43
+13.1%
16.7%€160.87€78.03n/a19
Jan ’26€84.40
€119.04
+41.0%
17.7%€158.30€76.78n/a19
Dec ’25€89.60
€118.57
+32.3%
17.7%€157.68€76.48n/a19
Nov ’25€80.22
€115.18
+43.6%
18.2%€153.54€74.47n/a18
Oct ’25€80.12
€114.10
+42.4%
16.7%€149.62€68.98n/a17
Sep ’25€83.20
€116.52
+40.0%
16.7%€152.79€70.45n/a17
Aug ’25€93.70
€115.13
+22.9%
16.7%€154.76€70.43n/a17
Jul ’25€102.20
€110.69
+8.3%
19.3%€155.74€69.53n/a17
Jun ’25€98.78
€110.69
+12.1%
19.3%€155.74€69.53n/a17
May ’25€86.20
€91.67
+6.3%
21.6%€121.52€46.74n/a17
Apr ’25€86.50
€89.14
+3.0%
21.6%€114.43€45.77n/a16
Mar ’25€90.50
€90.19
-0.3%
21.0%€116.01€46.41n/a17
Feb ’25€73.00
€83.40
+14.3%
21.9%€106.43€46.28€108.3017
Jan ’25€84.00
€77.55
-7.7%
23.5%€104.42€45.40€84.4017
Dec ’24€66.00
€73.29
+11.0%
21.4%€105.10€46.10€89.6018
Nov ’24€56.00
€74.41
+32.9%
20.7%€107.38€47.10€80.2218
Oct ’24€48.60
€69.50
+43.0%
26.1%€106.23€37.27€80.1217
Sep ’24€46.00
€67.92
+47.6%
25.9%€104.63€36.71€83.2017
Aug ’24€59.50
€67.67
+13.7%
26.4%€103.67€38.19€93.7017
Jul ’24€58.50
€67.01
+14.5%
27.7%€104.47€38.49€102.2017
Jun ’24€52.00
€67.94
+30.7%
27.7%€106.02€42.78€98.7817
May ’24€46.20
€62.21
+34.7%
32.9%€103.23€34.41€86.2017
Apr ’24€41.57
€64.25
+54.6%
33.0%€106.34€35.45€86.5017
Mar ’24€40.38
€65.07
+61.1%
32.9%€108.06€36.02€90.5017
Feb ’24€41.65
€69.35
+66.5%
33.6%€105.83€35.89€73.0017
Analyst Price Target
Consensus Narrative from 19 Analysts
€121.42
Fair Value
11.5% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/04 17:38
End of Day Share Price 2025/02/04 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Blueprint Medicines Corporation is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Ishan MajumdarBaptista Research
Peter LawsonBarclays